- Home
- NSIT vs BLCO Comparison
NSIT vs BLCO Comparison
Compare NSIT & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSIT
- BLCO
- Stock Information
- Founded
- NSIT 1988
- BLCO 1853
- Country
- NSIT United States
- BLCO Canada
- Employees
- NSIT N/A
- BLCO N/A
- Industry
- NSIT EDP Services
- BLCO Ophthalmic Goods
- Sector
- NSIT Technology
- BLCO Health Care
- Exchange
- NSIT Nasdaq
- BLCO Nasdaq
- Market Cap
- NSIT 4.3B
- BLCO 4.9B
- IPO Year
- NSIT 1995
- BLCO 2022
- Fundamental
- Price
- NSIT $140.78
- BLCO $13.71
- Analyst Decision
- NSIT Buy
- BLCO Hold
- Analyst Count
- NSIT 4
- BLCO 13
- Target Price
- NSIT $185.00
- BLCO $15.83
- AVG Volume (30 Days)
- NSIT 297.3K
- BLCO 786.3K
- Earning Date
- NSIT 07-31-2025
- BLCO 07-30-2025
- Dividend Yield
- NSIT N/A
- BLCO N/A
- EPS Growth
- NSIT N/A
- BLCO N/A
- EPS
- NSIT 5.12
- BLCO N/A
- Revenue
- NSIT $8,425,769,000.00
- BLCO $4,829,000,000.00
- Revenue This Year
- NSIT $3.19
- BLCO $6.97
- Revenue Next Year
- NSIT $4.72
- BLCO $5.48
- P/E Ratio
- NSIT $27.51
- BLCO N/A
- Revenue Growth
- NSIT N/A
- BLCO 11.94
- 52 Week Low
- NSIT $126.10
- BLCO $10.45
- 52 Week High
- NSIT $228.07
- BLCO $21.69
- Technical
- Relative Strength Index (RSI)
- NSIT 54.66
- BLCO 69.08
- Support Level
- NSIT $140.71
- BLCO $12.02
- Resistance Level
- NSIT $146.83
- BLCO $14.35
- Average True Range (ATR)
- NSIT 3.59
- BLCO 0.46
- MACD
- NSIT 0.32
- BLCO 0.15
- Stochastic Oscillator
- NSIT 54.75
- BLCO 85.82
About NSIT Insight Enterprises Inc.
Insight Enterprises Inc is a Fortune IT provider engaged in helping businesses of all sizes, large enterprises, governments, schools, and healthcare organizations. The company has three geographic operating segments: North America, EMEA, and APAC. It generates maximum revenue from the North America segment. The company provides digital innovation, cloud/data center transformation, connected workforce, and supply chain optimization solutions and services.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.